Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | GGH | Q92820 | 1/20 | 0.33 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.33 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3380416 | 0.81 | RIPK1 (0.42) | CYP2D6ALDH1A1CYP1A2TSHRCYP2C19 | |
| SCHEMBL3380418 | 0.76 | HDAC3 (0.50) | MAPTPOLBTSHRSMN1; SMN2 | |
| SCHEMBL3382276 | 0.74 | MAPT (0.50) | MAPTTSHRSMN1; SMN2 | |
| SCHEMBL3380370 | 0.74 | ALDH1A1 (0.39) | ALDH1A1CYP1A2TSHR | |
| SCHEMBL3056333 | 0.73 | GABBR2 (0.47) | MAPTPOLBCYP2D6ALDH1A1CYP1A2 | |
| SCHEMBL8585562 | 0.73 | NAALAD2 (0.40) | POLBCYP2D6ALDH1A1CYP1A2TSHR | |
| SCHEMBL8457132 | 0.73 | KEAP1 (0.41) | MAPTALDH1A1SMN1; SMN2FOLH1 | |
| SCHEMBL13137019 | 0.72 | MAPT (0.44) | MAPTPOLBCYP2D6ALDH1A1CYP1A2 | |
| SCHEMBL1377066 | 0.72 | FOLH1 (0.54) | FOLH1 | |
| SCHEMBL3382732 | 0.71 | AKR1B1 (0.39) | ALDH1A1CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5880112-A | PHOSPHINIC ACID DERIVATIVES; PROSTATE CANCER TREATMENT | GUILFORD PHARMACEUTICALS INC. (US) | 1999-03-09 | — | — | US | claimed |
| EP-1443954-B1 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | SCRIPPS RESEARCH INST (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7399743-B2 | Targeted thrombosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1443954-A2 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | Novartis Pharma GmbH (AT) | 2004-08-11 | — | — | EP | disclosed |
| US-20030194400-A1 | Targeted thrombosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-16 | — | — | US | disclosed |
| WO-2003035688-A2 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | NOVARTIS PHARMA GMBH (AT) | 2003-05-01 | — | — | WO | disclosed |
| US-5880112-A | PHOSPHINIC ACID DERIVATIVES; PROSTATE CANCER TREATMENT | GUILFORD PHARMACEUTICALS INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5804602-A | N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-09-08 | — | — | US | disclosed |
| US-5672592-A | HYDROLASE INHIBITORS, ANTITUMOR AND ANTICARCINOGENIC AGENTS, FOR PROSTATE CANCER | GUILFORD PHARMACEUTICALS INC. (US) | 1997-09-30 | — | — | US | disclosed |